ANXIETY RECONCEPTUALIZED
ANXIETY RECONCEPTUALIZED
复制标题
DOI:
10.1016/0010-440x(80)90043-7
复制
发表时间:
1980-01-01
影响因子:
7.3
通讯作者:
KLEIN, DF
中科院分区:
文献类型:
--
作者:
KLEIN, DF
EARLY EXPERIENCE WITH IMIPRAMINE AND ANXIETY I N 1959 I was studying the clinical effects of the mysterious new drug imipramine. The hope was that it would be another powerful agent, like the phenothiazines, for the treatment of schizophrenia. It failed, however, to alleviate schizophrenic symptoms although it raised the mood of depressed schizophrenics. Further, clinical trials on patients with severe depression led to excellent results. It was neither a tranquillizer, as initially conceived, nor a stimulant, as later hypothesized, but rather a mood normalizer. Its mode of action seemed the result of an interaction between the medication and the psychophysiological dysregulation that produced the pathological state. It occurred to us to try this new drug with a group of extremely anxious patients who did not evince delusions or hallucinations but who had proven refractory both to intensive psychotherapy and treatment with sedatives OI chlorpromazine. These patients today would be diagnosed as agoraphobic with panic attacks although, in the feckless habit of the time, they were then labeled schizophrenic because they had marked social impairment and severe symptoms.Several patients volunteered for a pilot trial with imipramine, primarily because anything was better than being sent home unimproved. Although both the patients and their therapists insisted for many days that no gains had been made, by the third week the ward staff noticed that patients no longer experienced their former episodes of severe anxiety. After a few more weeks their improvement became indisputable.